Replaces Prod. #: BML-CC201
Inactive negative control for use in studies involving olomoucine (Prod. No. ALX-350-013).
Product Specification
| Alternative Name: | 6-Benzylamino-2-(2-hydroxyethylamino)-7-methylpurine |
| |
| Formula: | C15H18N6O |
| |
| MW: | 298.3 |
| |
| CAS: | 101622-50-8 |
| |
| Purity: | ≥98% (TLC) |
| |
| Appearance: | Off-white solid. |
| |
| Solubility: | Soluble in DMSO or methanol. |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Store, as supplied, at -20°C for up to 1 year. Store solutions at -20°C for up to 3 months. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Inhibition of Cdk5 in the nucleus accumbens enhances the locomotor-activating and incentive-motivational effects of cocaine: J.R. Taylor, et al.; PNAS
104, 4147 (2007),
Abstract;
The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity: F. Alessi, et al.; Exp. Cell Res.
245, 8 (1998),
Abstract;
The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker: N.A. Krucher, et al.; Cell. Mol. Neurobiol.
17, 495 (1997),
Abstract;
Inhibition of cyclin-dependent kinases by purine analogues: J. Vesely, et al.; Eur. J. Biochem.
224, 771 (1994),
Abstract;
Related Products
